Pfizer to study pneumococcal, COVID-19 vaccine combo in older adults

By The Science Advisory Board staff writers

May 24, 2021 -- Pfizer has launched a study that is investigating the coadministration of the company's pneumococcal vaccine (20vPnC) and its Pfizer-BioNTech COVID-19 vaccine in adults 65 and older.

The main purpose of the study is to assess safety when both vaccines are administered together with a six-month follow-up. The trial includes 600 adults who will have received their second dose of Pfizer's COVID-19 vaccine at least six months before the coadministration study.

Participants will be randomized into three groups:

  • Pneumococcal vaccine plus COVID-19 vaccine booster
  • Pneumococcal plus a placebo
  • COVID-19 vaccine booster and a placebo

The Pfizer-BioNTech COVID-19 vaccine is based on messenger RNA (mRNA) technology and has been shipped to 91 countries and territories around the world as part of an emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA).

The company's pneumococcal vaccine was accepted for priority review for a biologics license application by the FDA in December 2020 and marketing authorization application review by the European Medicines Agency in February 2021. The vaccine includes capsular polysaccharide conjugates for 20 serotypes that are responsible for a majority of currently circulating pneumococcal disease globally.

FDA authorizes Pfizer-BioNTech COVID-19 vaccine for adolescents
The U.S. Food and Drug Administration (FDA) expanded the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine to include adolescents...
Pfizer, BioNTech initiate rolling submission of BLA for COVID-19 vaccine
Pfizer and BioNTech announced on Friday that they have started a biologics license application (BLA) with the U.S. Food and Drug Administration for approval...
Pfizer, BioNTech submit expanded CMA to EMA for COVID-19 vaccine
Pfizer and BioNTech announced on Friday they have submitted a variation to the conditional marketing authorization (CMA) for use of their COVID-19 vaccine...
Pfizer, BioNTech confirm high efficacy of COVID-19 vaccine up to 6 months
Pfizer-BioNTech's BNT162b2 COVID-19 vaccine is 91.3% effective against the virus six days through up to six months after the second dose, according to...
Pfizer-BioNTech's COVID-19 vaccine shows 100% effectiveness in adolescents
Pfizer-BioNTech's BNT162b2 COVID-19 vaccine demonstrated 100% efficacy and robust antibody responses in people between the ages of 12 and 15, according...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter